Write in a clean editor, then format for Expert Opinion on Emerging Drugs in one click — DocuGuru applies the official Taylor & Francis template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Expert Opinion on Emerging Drugs is a peer-reviewed journal published by Taylor & Francis, covering Asthma and respiratory diseases, Retinal Diseases and Treatments, Cancer Immunotherapy and Biomarkers.
| Publisher | Taylor & Francis |
|---|---|
| Reference style | Author–year (Chicago, T&F) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Expert Opinion on Emerging Drugs 12 (3): 45–58.
Formats any DOI in Expert Opinion on Emerging Drugs style. No sign-up. |
| Publishes research in | Asthma and respiratory diseases Retinal Diseases and Treatments Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations CAR-T cell therapy research |
| ISSN | 1472-8214 |
| Citation impact (2-yr) | 4.61 |
| h-index | 64 |
| i10-index | 590 |
| Total citations | 21,654 |
| Top institutions publishing here | Weatherford College |
| Journal website | informahealthcare.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
PEGylation is a pharmaceutical technology that involves the covalent attachment of polyethylene glycol (PEG) to a drug to improve its pharmacokinetic, pharmacodynamic, and immunological profiles, and thus, enhance its therapeutic effect. Currently, PEGylation is used to modify proteins, peptides, oligonucleotides, antibody fragments, and small organic molecules. Research groups are striving to improve the consistencies of…
The tremendous potential of biologic drugs is hampered by short half-lives in vivo, resulting in significantly lower potency than activity seen in vitro. These short-acting therapeutic agents require frequent dosing profiles that can reduce applicability to the clinic, particularly for chronic conditions. Therefore, half-life extension technologies are entering the clinic to enable improved or new…
BACKGROUND: This review summarizes promising approaches for the treatment of traumatic brain injury (TBI) that are in either preclinical or clinical trials. OBJECTIVE: The pathophysiology underlying neurological deficits after TBI is described. An overview of select therapies for TBI with neuroprotective and neurorestorative effects is presented. METHODS: A literature review of preclinical TBI studies and…
BACKGROUND: Obesity is a widespread disease in both the developed and developing world. Few pharmacological approaches for its treatment exist at this time. OBJECTIVE: This review summarises the currently approved obesity therapies and describes a possible new approach for the treatment and prophylaxis of this disease, based on the inhibition of carbonic anhydrases (CAs, EC…
Many of our 'small-molecule-drugs' are natural products from plants, or are synthetic compounds based on molecules found naturally in plants. However, the vast majority of the protein therapeutics (or biopharmaceuticals) we use are from animal or human sources, and are produced commercially in microbial or mammalian bioreactor systems. Over the last few years, it has…
